246 related articles for article (PubMed ID: 27816512)
1. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis.
Aimo A; Vergaro G; Passino C; Ripoli A; Ky B; Miller WL; Bayes-Genis A; Anand I; Januzzi JL; Emdin M
JACC Heart Fail; 2017 Apr; 5(4):280-286. PubMed ID: 27816512
[TBL] [Abstract][Full Text] [Related]
2. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.
Aimo A; Vergaro G; Ripoli A; Bayes-Genis A; Pascual Figal DA; de Boer RA; Lassus J; Mebazaa A; Gayat E; Breidthardt T; Sabti Z; Mueller C; Brunner-La Rocca HP; Tang WH; Grodin JL; Zhang Y; Bettencourt P; Maisel AS; Passino C; Januzzi JL; Emdin M
JACC Heart Fail; 2017 Apr; 5(4):287-296. PubMed ID: 28189578
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure.
Gül İ; Yücel O; Zararsız A; Demirpençe Ö; Yücel H; Zorlu A; Yılmaz MB
Anatol J Cardiol; 2017 Sep; 18(3):200-205. PubMed ID: 28761021
[TBL] [Abstract][Full Text] [Related]
4. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective.
Jenkins WS; Roger VL; Jaffe AS; Weston SA; AbouEzzeddine OF; Jiang R; Manemann SM; Enriquez-Sarano M
Am J Med; 2017 Sep; 130(9):1112.e9-1112.e15. PubMed ID: 28344136
[TBL] [Abstract][Full Text] [Related]
6. The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis.
Liu N; Hang T; Gao X; Yang W; Kong W; Lou Q; Yang J
PLoS One; 2020; 15(9):e0238775. PubMed ID: 32886697
[TBL] [Abstract][Full Text] [Related]
7. Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis.
Gu L; Li J
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31092701
[No Abstract] [Full Text] [Related]
8. Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis.
Guo G; Huang A; Huang X; Xu T; Yao L
Dis Markers; 2021; 2021():8881393. PubMed ID: 33574967
[TBL] [Abstract][Full Text] [Related]
9. Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2.
Somuncu MU; Kalayci B; Avci A; Akgun T; Karakurt H; Demir AR; Avci Y; Can M
Horm Mol Biol Clin Investig; 2020 Feb; 41(2):. PubMed ID: 32112700
[TBL] [Abstract][Full Text] [Related]
10. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
[TBL] [Abstract][Full Text] [Related]
11. Soluble ST2 and brain natriuretic peptide predict different mode of death in patients with heart failure and preserved ejection fraction.
Sugano A; Seo Y; Ishizu T; Sai S; Yamamoto M; Hamada-Harimura Y; Machino-Ohtsuka T; Obara K; Nishi I; Aonuma K; Nogami A
J Cardiol; 2019 Apr; 73(4):326-332. PubMed ID: 30580891
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
[TBL] [Abstract][Full Text] [Related]
13. sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction.
Plawecki M; Morena M; Kuster N; Chenine L; Leray-Moragues H; Jover B; Fesler P; Lotierzo M; Dupuy AM; Klouche K; Cristol JP
Mediators Inflamm; 2018; 2018():3952526. PubMed ID: 30402040
[TBL] [Abstract][Full Text] [Related]
14. Soluble ST2 proteins in male cachectic patients with chronic heart failure.
Sobieszek G; Powrózek T; Jaroszyński A; Skwarek-Dziekanowska A; Rahnama-Hezavah M; Małecka-Massalska T
Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):886-893. PubMed ID: 33549461
[TBL] [Abstract][Full Text] [Related]
15. Soluble ST2 protein and hospitalizations due to worsening chronic heart failure during a one-year follow-up in a population with reduced ejection fraction.
Wojtczak-Soska K; Sakowicz A; Pietrucha T; Janikowski K; Lelonek M
Adv Clin Exp Med; 2017 Sep; 26(6):931-938. PubMed ID: 29068593
[TBL] [Abstract][Full Text] [Related]
16. Long-Term and Short-Term Prognostic Value of Circulating Soluble Suppression of Tumorigenicity-2 Concentration in Chronic Heart Failure: A Systematic Review and Meta-Analysis.
Dong G; Chen H; Zhang H; Gu Y
Cardiology; 2021; 146(4):433-440. PubMed ID: 33902050
[TBL] [Abstract][Full Text] [Related]
17. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects.
Cardellini M; Rizza S; Casagrande V; Cardolini I; Ballanti M; Davato F; Porzio O; Canale MP; Legramante JM; Mavilio M; Menghini R; Martelli E; Farcomeni A; Federici M
Acta Diabetol; 2019 Mar; 56(3):273-280. PubMed ID: 30259114
[TBL] [Abstract][Full Text] [Related]
18. ST2 as a novel prognostic marker in end-stage renal disease patients on hemodiafiltration.
Homsak E; Ekart R
Clin Chim Acta; 2018 Feb; 477():105-112. PubMed ID: 29221927
[TBL] [Abstract][Full Text] [Related]
19. Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT.
Skali H; Gerwien R; Meyer TE; Snider JV; Solomon SD; Stolen CM
J Cardiovasc Transl Res; 2016 Dec; 9(5-6):421-428. PubMed ID: 27798759
[TBL] [Abstract][Full Text] [Related]
20. Impact of diabetes on the predictive value of heart failure biomarkers.
Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
